DNDN—Whether you characterize the problem as cash flow, reimbursement risk, cash density, or some other creative appellation, the salient point appears to be that the end-user demand for Provenge is less than many people thought until yesterday.
We will not see DNDN sporting a $5B+ enterprise value ever again, IMHO.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”